Compare Analog Devices, Inc. (ADI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Analog Devices, Inc. vs GeneDx Holdings Corp — how do they compare? Analog Devices, Inc. trades at $385.24 (market cap $184.62B), while GeneDx Holdings Corp trades at $65 (market cap $1.94B). The key difference: Analog Devices, Inc. is far larger — about 95.2× GeneDx Holdings Corp's market cap, and Analog Devices, Inc. pays a 1.16% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ADI | WGS | |
|---|---|---|
Market Cap | $184.62B | $1.94B |
Sector | Technology | Technology |
52-Week High | $445.48 | $167.51 |
52-Week Low | $220.68 | $34.51 |
Enterprise Value | $189.87B | $1.94B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Analog Devices (ADI) trades at $379.03, up 0.5% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q3-Q1 2026) and robust profitability (26% net margin). Recent acquisition of Empower Semiconductor and AI-driven semiconductor demand provide growth catalysts. Cash flow remains positive at $508M in 2025, though net cash flow is projected to decline to $61M in 2026.
Outlook remains positive with 79.6% analyst buy ratings and $471 consensus price target (24% upside). Key risks include elevated valuation multiples (P/E 57.9) and debt-to-asset ratio increase to 17.9%. The stock offers dividend income ($1.10 H1-26) while benefiting from semiconductor industry tailwinds, though margin sustainability and competitive pressures warrant monitoring.
GeneDx Holdings Corp. (WGS) trades at $68.89, up 2.04% today, with a bullish technical signal from moving averages and a consensus analyst price target of $75.40. Despite recent earnings beats in Q3 and Q4 2025, the company reported a net loss of -$21.02M in 2025, with profitability metrics like ROE at -30.42% reflecting operational challenges. The stock faces headwinds from a securities class action lawsuit alleging fraud, as noted in multiple legal alerts from July 2026.
The outlook is mixed: strong analyst buy ratings (90.91%) suggest upside potential, but negative margins and legal risks pose significant threats. Investors should weigh the high valuation multiples, such as EV/EBITDA of 161.17, against growth prospects in the genomics sector, with cash flow trends showing volatility into 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Analog Devices, Inc.
Analog Devices is a leading analog, mixed signal, and digital signal processing chipmaker. The firm has a significant market share lead in converter chips, which are used to translate analog signals to digital and vice versa. The company serves tens of thousands of customers, and more than half of its chip sales are made to industrial and automotive end markets. Analog Devices' chips are also incorporated into wireless infrastructure equipment.
Read more on ADI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
